Navigation Links
Lialda in Medical News

Long-term safety data on Lialda published in leading GI journal

Basingstoke, UK and Philadelphia, US June 17, 2008 Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda™...

New Analyses of long-term LIALDA (mesalamine) data presented at ACG

Philadelphia, PA October 15, 2007 Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate u...

Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans

...nts who are newly prescribed or are already taking lialda or Pentasa and who become unemployed in 2009 can r...ar. In addition, more UC patients can benefit from lialda and Pentasa because Shire has raised the household...am (not valid in Mass.) and a 30-day free trial of lialda when patients join the...

Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease

...rapy for patients with mild disease. Among oral 5-aminosalicylates, Shire's lialda has more convenient dosing. Because of this clinical advantage, surveyed physicians indicated that they intend to move patients to lialda from both Procter & Gamble/Giuliani's Asacol and Shire/Ferring/Nisshin/Kyor...

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal

...tudy were to assess the safety and tolerability of lialda in mild-to-moderate UC patients over 12 months. Da...terology. "This published data demonstrates that lialda is generally well tolerated and has a strong safet... the 303 study show that a majority of patients on lialda continued to remain in remission through 12 months...

Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis

...ith UC will develop colon cancer. About LIALDA lialda is part of a drug class called aminosalicylates, w...of choice and often a first-line treatment for UC. lialda is indicated for the induction of remission in pat...e, mild to moderate UC. The safety and efficacy of lialda have been established for up to eight weeks. LIALD...

Nationwide survey reveals differing physician and patient perceptions regarding impact of UC

...tions on Remission Management and Lifestyle), were sponsored by Shire Pharmaceuticals, a specialty biopharmaceutical company, which markets once-daily lialda and PENTASA (mesalamines) for UC. Before these surveys, patient and physician views on UCs impact had not been compared and the real-life impact o...

Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives

...ssen the burden," said Dr. Rubin. About LIALDA lialda is part of a drug class called aminosalicylates, w...of choice and often a first-line treatment for UC. lialda is indicated for the induction of remission in pat...e, mild to moderate UC. The safety and efficacy of lialda have been established for up to eight weeks. LIALD...

Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track

... 43.7 18% 2% 17% lialda 16.3 n/a n/a ...price increases in November 2006 and August 2007. lialda - Ulcerative colitis Shire launched lialda during March 2007. By September 30, 2007 LIALDA ha...

LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon

..., NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis drug lialda (mesalamine) demonstrated a delivery system where ...erative colitis. In this in vitro model, after the lialda tablet passed through the simulated stomach, small...n adult GI tract, we were able to demonstrate that lialda tablets provide maximum release of 5-ASA in a prol...
Lialda in Medical Technology

Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW

Post-hoc analysis shows nearly nine out of ten patients taking once-daily Lialda remained relapse free at the end of 12 months WASHINGTON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- A long-term phase III, open-label 12-14 month extension study (303) presented at the British Society of Gastroente...

Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week

... of therapy for continuing patients, 20 percent of lialda patients were continually persistent, 9 percent of...tion of the prescription that preceded the refill. lialda is an FDA-approved, once-daily oral medication for...cerative colitis (UC). Safety and effectiveness of lialda beyond eight weeks have not been established. ...

Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW

...om St Mark's Hospital in London, UK), demonstrated lialda was effective in inducing remission in patients wi... 8-week study. Patients in the Kamm study received lialda 2.4g/day once daily (n=84), 4.8g/day once daily (n... the definition used for remission, treatment with lialda 2.4g/day, or 4.8g/day, or Asacol 2.4g/day resulted...

New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG

...ug LIALDA(TM) (mesalamine) provide further data on lialda in patients with mild to moderate ulcerative colit...3 was safety and tolerability and findings -- that lialda is generally well tolerated in mild to moderate UC...tland in March 2007. "Earlier studies showed that lialda is well-tolerated and effective at inducing remiss...

Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life

... people with UC will develop colon cancer. About lialda lialda is part of a drug class called aminosalicylates, w...of choice and often a first-line treatment for UC. lialda is indicated for the induction of remission in pat...
Lialda in Biological Technology

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... 4.9 n/a n/a n/a(5) n/a(5) lialda / MEZAVANT 54.6 71% 73% ... 54.0 44.8 21% 8% lialda / MEZAVANT 54.6 32.0 7... 105.2 89.0 18% 7% lialda / MEZAVANT 104.0 59.2 76...

Shire begins the year with a strong performance

...ncome within revenues. License agreement for lialda in Japan - On January 16, 2009 Shire announce...LDA(R) (mesalamine) in Japan. Termination of lialda co-promotion agreement - As of March 31, 2009...tical Products Inc., for the co-promotion of lialda in the US. Pipeline DAYTRANA - for the t...

Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion

... Pharmaceutical Co., Ltd to develop and sell lialda in Japan. - On February 9, 2009 Shire announc... 78.7 +23% -11% 1.8% lialda / MEZAVANT 140.4 +178% +204% ...er 31, 2008 (2007: 21.1%), driven by the growth of lialda since its launch in March 2007. LIALDA/MEZA...

Shire's New Product Portfolio Delivers Strong Quarterly Performance

... first time. The performance of ELAPRASE, VYVANSE, lialda and FOSRENOL ROW were particularly strong. This qu... 18.1 93% -14% 1.6% lialda / MEZAVANT 40.4 148% +143% ...er 30, 2008 (2007: 22.5%), driven by the growth of lialda since its launch in March 2007. The overall US ora...

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.

...oduct sales comprise DAYTRANA, ELAPRASE, FOSRENOL, lialda / MEZAVANT and VYVANSE Angus Russell, Chief...Products Inc. ("TAP") commenced co-promotion of lialda in the US in accordance with the co-promotion a... 22.6 14% -11% 1.8% lialda / MEZAVANT 32.0 n/a n/a ...

Cadient Group Recognized with Five Awards at 14th Annual Communicator Awards

...mpaigns." Cadient Group received the following Communicator Awards: -- lialda - Silver Communicator Award Cadient Group was recognized for its work with Shire US, Inc.'s lialda Web site, which offers information, tools, and resources for people ...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

...uency of our sales calls. Shire's GI team has made lialda the fastest growing brand of mesalamine and with t...VANT(R) - Ulcerative Colitis - By April 11, 2008 lialda had achieved a 9.8% share of the US oral mesalamin...hire's share of the US oral mesalamine market from lialda and PENTASA combined increased to 26.1% for the th...

Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis

...of 120 representatives who are currently detailing lialda primarily to gastroenterologists. "Aligning with...mendous benefit for Shire as it will quadruple the lialda sales force across the United States," said Mike Y...th messages about Lialda. Shire's GI team has made lialda the fastest growing brand of mesalamine and with t...

Shire plc: IFRS Results for the Year Ending December 31, 2007

...LDA/MEZAVANT - Ulcerative colitis Shire launched lialda in the US oral mesalamine market in March 2007, and by December 31, 2007 lialda had reached a market share of 8.0% (average annual...were US$50.5 million. All initial launch stocks of lialda totaling US$34.3 million were recognised into reve...

Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%

...ertook three major new product launches - VYVANSE, lialda / MEZAVANT and DYNEPO - which have gone well and a...hire's share of the US oral mesalamine market from lialda and PENTASA(R) combined was 26.0% at February 8, 2... 176.4 +28% +3% 17.2% lialda 50.5 n/a n/a ...
Other Tags
(Date:7/23/2014)... 23, 2014 Picnic Lunches, Residents of The ... outdoor concerts and festivals, while still dining on the fabulous ... concerts in the park or to the beach or museum ... great meal while they’re out,” said Brian Hughes, director of ... the residents are just loving.” , Hagopian, the executive chef ...
(Date:7/23/2014)... childbirth and post delivery may reduce the risk of ... perinatal psychiatrist, in a July 23 editorial in ... based on a new Chinese study that found women ... vaginal delivery had a much lower risk for postpartum ... "Maximizing pain control in labor and delivery with your ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Men and ... often spend a portion of their disposable income each ... is now promoting its best anti aging products guide ... , This products guide is now released and accessible ... Internet connection. Known retailers were selected and inserted into ...
(Date:7/22/2014)... Ticket Down is a reliable ... tickets at Sporting Park in Kansas City, MO. ... 23rd. Tickets can be conveniently printed out for this ... can be reached toll free at 1-877-870-3653. All tickets ... covered by Ticket Down's customer satisfaction guarantee. , About TicketDown.com: ...
(Date:7/22/2014)... (PRWEB) July 23, 2014 Recently, iFitDress.com, a ... women, has announced its new selection of white party ... announced that custom made outfits are now available on its ... order before the end of July can get a discounted ... company’s products are popular among international customers, so its marketing ...
Breaking Medicine News(10 mins):Health News:Chicago’s The Clare Retirement Community Announces New Summertime Culinary Programs 2Health News:Controlling childbirth pain tied to lower depression risk 2Health News:Best Anti Aging Products Guide Launched for Natural Product Buyers Online at News Portal 2Health News:Sporting Kansas City vs. Manchester City Tickets: Ticket Down Has Slashed Ticket Prices for Manchester City vs. Sporting Kansas City on July 23rd 2Health News:Elegant White Party Dresses Now Provided by Distinguished Company iFitDress.com 2
(Date:7/22/2014)... DURHAM, N.C. In a cost-effectiveness analysis of commercial ... the drug Qsymia showed the best value for the ... loss, but was also the most expensive option tested, ... Graduate Medical School. , The findings, published in the ... important information on the health and weight-loss benefits per ...
(Date:7/22/2014)... NEW YORK, NY -- As part of a multinational, ... at Mount Sinai have helped identify over 100 locations ... developing schizophrenia, in the largest genomic study published on ... The findings, published online in Nature , point ... and could lead to new approaches to treating the ...
(Date:7/22/2014)... have adapted to New York City,s human behaviour, allowing ... than their fellow squirrels in the woods. , Dr ... & Agriculture, led the study that proved eastern grey ... environments and prevent unnecessary responses when humans acted in ... , "As we rapidly increase the spread of ...
Breaking Biology News(10 mins):Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3Mount Sinai scientists and international team shed new light on schizophrenia 2Mount Sinai scientists and international team shed new light on schizophrenia 3New York squirrels are nuts about city life 2
Other Contents